JP2002515439A - 脳腫瘍の治療のためのエーデルホシン - Google Patents

脳腫瘍の治療のためのエーデルホシン

Info

Publication number
JP2002515439A
JP2002515439A JP2000549264A JP2000549264A JP2002515439A JP 2002515439 A JP2002515439 A JP 2002515439A JP 2000549264 A JP2000549264 A JP 2000549264A JP 2000549264 A JP2000549264 A JP 2000549264A JP 2002515439 A JP2002515439 A JP 2002515439A
Authority
JP
Japan
Prior art keywords
treatment
brain
tumors
tumor
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000549264A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002515439A5 (https=
Inventor
ナーグラー アポロニア
Original Assignee
メドマルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メドマルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical メドマルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2002515439A publication Critical patent/JP2002515439A/ja
Publication of JP2002515439A5 publication Critical patent/JP2002515439A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2000549264A 1998-05-19 1999-05-11 脳腫瘍の治療のためのエーデルホシン Pending JP2002515439A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19822509A DE19822509A1 (de) 1998-05-19 1998-05-19 Edelfosin zur Behandlung von Hirntumoren
DE19822509.1 1998-05-19
PCT/EP1999/003241 WO1999059599A1 (de) 1998-05-19 1999-05-11 Edelfosin zur behandlung von hirntumoren

Publications (2)

Publication Number Publication Date
JP2002515439A true JP2002515439A (ja) 2002-05-28
JP2002515439A5 JP2002515439A5 (https=) 2006-07-13

Family

ID=7868323

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000549264A Pending JP2002515439A (ja) 1998-05-19 1999-05-11 脳腫瘍の治療のためのエーデルホシン

Country Status (6)

Country Link
US (1) US6514519B1 (https=)
EP (1) EP1079838B1 (https=)
JP (1) JP2002515439A (https=)
AT (1) ATE223721T1 (https=)
DE (2) DE19822509A1 (https=)
WO (1) WO1999059599A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509293A (ja) * 2006-11-10 2010-03-25 アルファプトーゼ ゲーエムベーハー トリ置換グリセロール化合物を含む経口投与剤形
JP2013227341A (ja) * 2006-11-10 2013-11-07 Radioprotect Alphaptose Ug (Haftungsbeschraenkt) & Co Kg 放射線傷害治療のための三置換グリセロール化合物の使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531534A (ja) * 1998-12-04 2002-09-24 マックス−デルブルック−セントラム フュール モレクラーレ メディツィン タモキシフェン含有リポソーム系腫瘍治療剤
US7041302B2 (en) 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
JP2008539721A (ja) * 2005-05-02 2008-11-20 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク アルツハイマー病の治療のためのホスホイノシチドモジュレーション
DE102006019907A1 (de) * 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung
CA2669012C (en) * 2006-11-10 2017-06-20 Alphaptose Gmbh Combinations of edelfosine and anti-cancer agents for treatment of cancer
WO2008074573A1 (en) * 2006-12-20 2008-06-26 Alphaptose Gmbh Topical dosage form comprising tri-substituted glycerol compounds
CA2673040C (en) 2006-12-20 2016-02-02 Universitaetsklinikum Hamburg-Eppendorf Use of tri-substituted glycerol compounds for the treatment of hematological malignancies
AU2008254328A1 (en) 2007-05-18 2008-11-27 The Johns Hopkins University A treatment simulator for brain diseases and method of use thereof
RU2382765C1 (ru) * 2008-10-24 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" Rac-N,N-ДИМЕТИЛ-N-[2-(5-N',N'- ДИМЕТИЛАМИНОНАФТАЛЕН-1-СУЛЬФОНИЛОКСИ)ЭТИЛ]-N- {4-[(2-МЕТОКСИ-3-ОКТАДЕЦИЛОКСИ)ПРОП-1-ИЛОКСИКАРБОНИЛ]БУТИЛ} АММОНИЙИОДИД
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05502878A (ja) * 1990-01-03 1993-05-20 メドマルク　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 静脈内適用可能なｅｔ１８―ｏｃｈ↓３の医薬調合物
JPH05504132A (ja) * 1989-12-12 1993-07-01 メドマルク　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 活性化されたリンパ球の除去

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
WO1997035588A1 (en) * 1996-03-27 1997-10-02 Uab Research Foundation Novel uses of phospholipase c inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05504132A (ja) * 1989-12-12 1993-07-01 メドマルク　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 活性化されたリンパ球の除去
JPH05502878A (ja) * 1990-01-03 1993-05-20 メドマルク　ファルマ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング 静脈内適用可能なｅｔ１８―ｏｃｈ↓３の医薬調合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6009057070, ＥＮＧＥＢＲＡＡＴＥＮ，Ｏ． ｅｔ ａｌ, "Ｅｆｆｅｃｔ ｏｆ ａｌｋｙｌ−ｌｙｓｏｐｈｏｓｐｈｏｌｉｐｉｄ ｏｎ ｇｌｉｏｂｌａｓｔｏｍａ ｃｅｌｌ ｉｎｖａｓｉｏｎ ｉｎｔｏ ｆｅｔａｌ ｒａｔ ｂｒａｉｎ ｔｉｓｓｕｅ ｉｎ ｖｉｔｒｏ", Ｃａｎｃｅｒ Ｒｅｓ, 1991, Ｖｏｌ．５１， Ｎｏ．６, ｐ．１７１３−９ *
JPN6009057071, ＢＥＲＤＥＬ，Ｗ．Ｅ． ｅｔ ａｌ, "Ｃｙｔｏｔｏｘｉｃｉｔｙ ｏｆ ａｌｋｙｌ−ｌｙｓｏｐｈｏｓｐｈｏｌｉｐｉｄ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｌｏｗ−ａｌｋｙｌ−ｃｌｅａｖａｇｅ ｅｎｚｙｍｅ ａｃｔｉｖｉｔｉｅｓ ｉｎ ｒａｔ ｂ", Ｃａｎｃｅｒ Ｒｅｓ, 1983, Ｖｏｌ．４３， Ｎｏ．２, ｐ．５４１−５ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509293A (ja) * 2006-11-10 2010-03-25 アルファプトーゼ ゲーエムベーハー トリ置換グリセロール化合物を含む経口投与剤形
JP2013227341A (ja) * 2006-11-10 2013-11-07 Radioprotect Alphaptose Ug (Haftungsbeschraenkt) & Co Kg 放射線傷害治療のための三置換グリセロール化合物の使用

Also Published As

Publication number Publication date
ATE223721T1 (de) 2002-09-15
DE19822509A1 (de) 1999-11-25
DE59902666D1 (de) 2002-10-17
EP1079838B1 (de) 2002-09-11
WO1999059599A1 (de) 1999-11-25
EP1079838A1 (de) 2001-03-07
US6514519B1 (en) 2003-02-04

Similar Documents

Publication Publication Date Title
JP2024026262A (ja) 放射線感受性組織における細胞保護薬の選択的堆積およびその使用
JP2002515439A (ja) 脳腫瘍の治療のためのエーデルホシン
US20190321311A1 (en) Cancer Treatment by Simultaneous Targeting Energy Metabolism and Intracellular pH
CN110652514A (zh) 第三代egfr抑制剂的制药用途
Streiff et al. Phase I study of N1-N11-diethylnorspermine (denspm) administered tid for 6 days in patients with advanced malignancies
CN103491952A (zh) 用于治疗癌症的新颖联合疗法
TWI835050B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
JP5650193B2 (ja) 胸腺腫の治療のためのキナーゼ阻害剤の使用
US20180169123A1 (en) Combination therapy with a flavagline and 2-deoxyglucose
CN110312508A (zh) 含有棉酚和苯乙双胍作为活性成分的预防和治疗胰腺癌的药物组合物
JP2022529949A (ja) ミトコンドリア標的化及び抗癌治療のためのアルキルｔｐｐ化合物
CN109152766A (zh) 用于增殖性疾病的组合疗法
CN111728974B (zh) 西奥罗尼用于小细胞肺癌的治疗
US20210205272A1 (en) Dosing regimens for treatment of solid tumors having one or more genetic alterations in fgfr1, fgfr2, and/or fgfr3
JP2022507260A (ja) Ｍｃｌ－１阻害剤とミドスタウリンとの組み合わせ、その使用及び医薬組成物
Toker et al. Oral sirolimus for the treatment of juvenile xanthogranuloma: Report of two pediatric cases
US10111876B2 (en) ALK Kinase Inhibitor and its use
JP7854213B2 (ja) ミトコンドリア標的化及び抗癌治療のためのアルキルｔｐｐ化合物
WO2008016660A2 (en) Imidazoacridine compounds for treating leukemias
WO2026065490A1 (zh) Mitoxantrone在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
Uckun et al. Anti-cancer activity profile of 3’-azidothymidine 5’-[p-methoxyphenyl methoxyalaninyl phosphate](Compound 003), a novel nucleoside analog
WO2026065486A1 (zh) Quisinostat在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法
CN117597129A (zh) 氨基吡唑并嘧啶化合物在治疗trk激酶介导的肿瘤中的用途
JP2008501785A (ja) 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
CN120476129A (zh) 配位化合物、组合物及其用于治疗癌症的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060511

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100212

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100811